References
- Steen VD, Medsger TA. Changes in causes of death in systemic sclerosis, 1972–2002. Ann Rheum Dis 2007;66:940–4.
- Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE, Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006;354:2655–66.
- Hoyles RK, Ellis RW, Wellsbury J, Lees B, Newlands P, Goh NSL, A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum 2006;54:3962–70.
- Plastiras SC, Vlachoyiannopoulos PG, Tzelepis GE. Mycophenolate mofetil for interstitial lung disease in scleroderma. Rheumatology (Oxford) 2006;45:1572.
- Spiera RF, Gordon JK, Mersten JN, Magro CM, Mehta M, Wildman HF, Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trial. Ann Rheum Dis 2011;70:1003–9.
- Bussone G, Mouthon L. Interstitial lung disease in systemic sclerosis. Autoimmun Rev 2011;10:248–55.
- Nacci F, Righi A, Conforti ML, Miniati I, Fiori G, Martinovic D, Intravenous immunoglobulins improve the function and ameliorate joint involvement in systemic sclerosis: a pilot study. Ann Rheum Dis 2007;66:977–9.
- Blank M, Levy Y, Amital H, Shoenfeld Y, Pines M, Genina O, The role of intravenous immunoglobulin therapy in mediating skin fibrosis in tight skin mice. Arthritis Rheum 2002;46:1689–90.
- Nimmerjahn F, Ravetch JV. Anti-inflammatory actions of intravenous immunoglobulin. Annu Rev Immunol 2008;26:513–33.
- Bakewell CJ, Raghu G. Polymyositis associated with severe interstitial lung disease: remission after three doses of IV immunoglobulin. Chest 2011;139:441–3.